These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 7561360

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Role of diphosphonates in the therapy of osteolysis and malignant hypercalcemia].
    Delmas PD, Charhon SA, Chapuy MC, Meunier PJ.
    Rev Rhum Mal Osteoartic; 1984 Dec 15; 51(11):663-6. PubMed ID: 6523018
    [No Abstract] [Full Text] [Related]

  • 3. [Effect of bisphosphonate on myeloma bone disease].
    Abe M, Matsumoto T, Kosaka M.
    Rinsho Ketsueki; 2002 May 15; 43(5):349-52. PubMed ID: 12096484
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Management of myeloma with bisphosphonates.
    Bataille R.
    N Engl J Med; 1996 Feb 22; 334(8):529-30. PubMed ID: 8559209
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Multiple myeloma: primary bone tumor with systemic manifestations.
    Bilsky MH, Azeem S.
    Neurosurg Clin N Am; 2008 Jan 22; 19(1):31-40. PubMed ID: 18156045
    [Abstract] [Full Text] [Related]

  • 12. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
    Terpos E, Dimopoulos MA, Berenson J.
    Crit Rev Oncol Hematol; 2011 Feb 22; 77 Suppl 1():S13-23. PubMed ID: 21353176
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Use of pamidronate for multiple myeloma osteolytic lesions.
    Man Z, Otero AB, Rendo P, Barazzutti L, Sanchez Avalos JC.
    Lancet; 1990 Mar 17; 335(8690):663. PubMed ID: 1969040
    [No Abstract] [Full Text] [Related]

  • 15. [Salmon calcitonin in supportive therapy of neoplastic osteolysis. Preliminary report on a case of myeloma].
    Andriani A, Beni A, Beni RA, Calistri A, Gelli GF.
    Clin Ter; 1981 Jan 31; 96(2):183-91. PubMed ID: 7237953
    [No Abstract] [Full Text] [Related]

  • 16. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
    Croucher PI, Shipman CM, Van Camp B, Vanderkerken K.
    Cancer; 2003 Feb 01; 97(3 Suppl):818-24. PubMed ID: 12548581
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of bortezomib on bone disease in multiple myeloma.
    Drake MT, Rajkumar SV.
    Am J Hematol; 2009 Jan 01; 84(1):1-2. PubMed ID: 19030185
    [No Abstract] [Full Text] [Related]

  • 19. Supportive care in myeloma.
    Berenson JR.
    Clin Adv Hematol Oncol; 2004 Sep 01; 2(9):569, 571. PubMed ID: 16163246
    [No Abstract] [Full Text] [Related]

  • 20. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
    Ciepłuch H, Baran W, Hellmann A.
    Med Sci Monit; 2002 Apr 01; 8(4):PI31-6. PubMed ID: 11951079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.